Nicholas Investment Partners’s Roivant Sciences ROIV Stock Holding History

Nicholas Investment Partners’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.8M	Buy	419,280 +140,855	+51%	+$4.16M	0.84%	37
2026 Q1	$7.71M	Sell	278,425 -1,431	-0.5%	-$36.8K	0.56%	65
2025 Q4	$6.07M	Buy	279,856 +34,235	+14%	+$675K	0.44%	82
2025 Q3	$3.72M	Buy	+245,621	New	+$3.04M	0.28%	124
2024 Q1	–	Sell	-158,015	Closed	-$1.77M	–	221
2023 Q4	$1.77M	Sell	158,015 -2,840,120	-95%	-$27.7M	0.21%	142
2023 Q3	$35M	Buy	2,998,135 +732,812	+32%	+$8.28M	2.62%	5
2023 Q2	$22.8M	Buy	2,265,323 +1,192,940	+111%	+$10.7M	1.56%	21
2023 Q1	$7.91M	Buy	+1,072,383	New	+$8.83M	0.6%	48

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Nicholas Investment Partners's ROIV Position: Q2 2026 in Review

Nicholas Investment Partners increased its Roivant Sciences (ROIV) stake by 51% in Q2 2026, buying an estimated $4.16M and bringing the position to 419,280 shares worth $14.8M. The position accounts for 0.84% of the portfolio, ranked #37.

Nicholas Investment Partners first reported a position in ROIV in Q1 2023 and has held it in 8 quarters since. The position peaked at $35M in Q3 2023. 499 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Nicholas Investment Partners held 419,280 shares of Roivant Sciences worth $14.8M as of Q2 2026.
Nicholas Investment Partners bought 140,855 Roivant Sciences shares in Q2 2026, an estimated $4.16M.
Roivant Sciences made up 0.84% of Nicholas Investment Partners's portfolio in Q2 2026, its #37 holding.
Nicholas Investment Partners first reported a position in Roivant Sciences in Q1 2023 and has held it in 8 quarters since.
Nicholas Investment Partners's Roivant Sciences position peaked at $35M in Q3 2023.
499 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Nicholas Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.